M
M01AX01 Nabumetone
[M01AX] Other antiinflammatory and antirheumatic agents, non-steroids
[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
[M] Musculoskeletal system
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
![]() ![]() ![]() |
Warning |
Aggregated GHS information provided by 7 companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 1 of 7 companies. For more detailed information, please visit ECHA C&L website Of the 6 notification(s) provided by 6 of 7 companies with hazard statement code(s): H302 (33.33%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (33.33%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (16.67%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H332 (16.67%): Harmful if inhaled [Warning Acute toxicity, inhalation] H335 (16.67%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] H361 (33.33%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H373 (16.67%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] H400 (16.67%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (50%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] H411 (16.67%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P261, P264, P270, P271, P273, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P314, P321, P330, P332+P313, P337+P313, P362, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | skin and appendages (skin): "dermatitis, other: after systemic exposure" | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. |
| monkey | LD50 | oral | 3200mg/kg (3200mg/kg) | gastrointestinal: changes in structure or function of salivary glands | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. |
| rat | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | skin and appendages (skin): "dermatitis, other: after systemic exposure" | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. |
| rat | LD50 | oral | 3880mg/kg (3880mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. | |
| rat | LD50 | intraperitoneal | 1520mg/kg (1520mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. | |
| mouse | LD50 | intraperitoneal | 2380mg/kg (2380mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. | |
| women | TDLo | oral | 1260mg/kg/6W- (1260mg/kg) | Postgraduate Medical Journal. Vol. 67, Pg. 1021, 1991. | |
| monkey | LD50 | oral | 3200mg/kg (3200mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. | |
| mouse | LD50 | oral | 4290mg/kg (4290mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 2939, 1988. | |
| 2-Butanone, 4-(6-methoxy-2-naphthalenyl)- | 4-(2-Methoxynaphthalen-6-yl)butan-2-one | 4-(6-Methoxy-2-naphthalenyl)-2-butanone |
| 4-(6-Methoxy-2-naphthyl)-2-butanone | 4-(6-methoxy-2-naphthyl)butan-2-one | 4-(6-methoxynaphthalen-2-yl)butan-2-one |
| 4-[6-methoxy-2-naphthyl]-2-butanone | 42924-53-8 | 924N538 |
| AB00052392 | AB00052392-13 | AB00052392_14 |
| AB00052392_15 | AC-19025 | AK-86115 |
| AKOS009529199 | AM20040460 | ANW-46490 |
| API0003472 | AX8142896 | Arthaxan |
| BC966361 | BCP12152 | BDBM40128 |
| BIDD:GT0104 | BLXXJMDCKKHMKV-UHFFFAOYSA-N | BPBio1_000834 |
| BRD-K65146499-001-04-8 | BRD-K65146499-001-14-7 | BRL 14777 |
| BRL-14777 | BRL14777 | BRN 2103472 |
| BSPBio_000758 | Balmox | C-13097 |
| CAS-42924-53-8 | CC-32257 | CCG-39507 |
| CCRIS 8108 | CHEBI:7443 | CHEMBL1070 |
| CPD000058835 | CS-2669 | CTK8B4843 |
| Consolan | D00425 | DB00461 |
| DSSTox_CID_25472 | DSSTox_GSID_45472 | DSSTox_RID_80901 |
| DTXSID4045472 | DivK1c_000850 | Dolsinal |
| FT-0629765 | Flambate | GTPL7245 |
| HMS1570F20 | HMS1922G10 | HMS2090D13 |
| HMS2093I05 | HMS2097F20 | HMS2230H12 |
| HMS3259I16 | HMS3652M04 | HMS3714F20 |
| HMS502K12 | HY-B0559 | IDI1_000850 |
| KBio1_000850 | KBio2_001966 | KBio2_004534 |
| KBio2_007102 | KBioGR_000687 | KBioSS_001966 |
| KS-1371 | LS-46825 | LW0TIW155Z |
| Listran | M727 | MFCD00079518 |
| MLS000069541 | MLS001076325 | Mebutan |
| NC00579 | NCGC00016853-01 | NCGC00016853-02 |
| NCGC00016853-03 | NCGC00016853-06 | NCGC00095063-01 |
| NCGC00095063-02 | NINDS_000850 | NSC-758623 |
| NSC758623 | Nabumatone Form II | Nabumetona |
| Nabumetone (JP17/USP/INN) | Nabumetone [USAN:BAN:INN:JAN] | Nabumetone [USAN:USP:INN:BAN:JAN] |
| Nabumetone, British Pharmacopoeia (BP) Reference Standard | Nabumetone, European Pharmacopoeia (EP) Reference Standard | Nabumetone, United States Pharmacopeia (USP) Reference Standard |
| Nabumetone, analytical standard | Nabumetonum | Nabumetonum [INN-Latin] |
| Nabuser | Opera_ID_765 | Pharmakon1600-01503650 |
| Prestwick0_000909 | Prestwick1_000909 | Prestwick2_000909 |
| Prestwick3_000909 | Prodac | Q425207 |
| Relafen | Relafen (TN) | Relif |
| Relifen | Relifex | SAM002564225 |
| SBI-0051869.P002 | SC-77045 | SCHEMBL2256 |
| SMR000058835 | SPBio_002097 | SPBio_002957 |
| SPECTRUM1503650 | SR-01000759138 | SR-01000759138-2 |
| SR-01000759138-3 | ST2405403 | SW197312-3 |
| Spectrum2_001969 | Spectrum4_000174 | Spectrum5_001286 |
| Spectrum_001486 | TC-135235 | Tox21_110647 |
| Tox21_110647_1 | UNII-LW0TIW155Z | Unimetone |
| ZINC20221 | cid_4409 | nabumeton |
| nabumetone | s4051 |
| DrugBank Name | Nabumetone |
| DrugBank | DB00461 |
| CAS Number | 1216770-08-9, 42924-53-8 |
| PubChem Compound | 4409 |
| KEGG Drug | D00425 |
| PubChem.Substance | 46507729 |
| ChEBI | 7443 |
| PharmGKB | PA450572 |
| ChemSpider | 4256 |
| BindingDB | 40128.0 |
| TTD | DAP000735 |
| Wikipedia | Nabumetone |
| HET | NBO |
| DPD | 946 |